CN101578111A - 禽流感疫苗和使用方法 - Google Patents
禽流感疫苗和使用方法 Download PDFInfo
- Publication number
- CN101578111A CN101578111A CNA2007800136387A CN200780013638A CN101578111A CN 101578111 A CN101578111 A CN 101578111A CN A2007800136387 A CNA2007800136387 A CN A2007800136387A CN 200780013638 A CN200780013638 A CN 200780013638A CN 101578111 A CN101578111 A CN 101578111A
- Authority
- CN
- China
- Prior art keywords
- asn
- leu
- ser
- glu
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 229960005486 vaccine Drugs 0.000 title claims abstract description 47
- 206010064097 avian influenza Diseases 0.000 title claims abstract description 27
- 208000002979 Influenza in Birds Diseases 0.000 title claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 85
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 71
- 229920001184 polypeptide Polymers 0.000 claims abstract description 69
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 241000282414 Homo sapiens Species 0.000 claims abstract description 10
- 230000001681 protective effect Effects 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 30
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 2
- 101710146287 Hemagglutinin 1 Proteins 0.000 claims 21
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 19
- 230000009261 transgenic effect Effects 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 4
- 229960003971 influenza vaccine Drugs 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 91
- 210000004027 cell Anatomy 0.000 description 81
- 108020004414 DNA Proteins 0.000 description 39
- 241000700605 Viruses Species 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 31
- 239000000427 antigen Substances 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 102220023256 rs387907547 Human genes 0.000 description 24
- 239000000523 sample Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 101710154606 Hemagglutinin Proteins 0.000 description 15
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 15
- 101710176177 Protein A56 Proteins 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 239000002773 nucleotide Chemical group 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 102220023257 rs387907546 Human genes 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000000185 hemagglutinin Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 102220004457 rs11567847 Human genes 0.000 description 11
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 10
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000004531 microgranule Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 102220369447 c.1352G>A Human genes 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102220023258 rs387907548 Human genes 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000589158 Agrobacterium Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- ZADHKSJXSZBQFB-HHHXNRCGSA-N lipid fragment Chemical compound CC(C)CCCCCCCCCCCC[C@@H](C)CCCCCCCC(C)C ZADHKSJXSZBQFB-HHHXNRCGSA-N 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101710133359 Agglutinin receptor Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010381 tandem affinity purification Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000005418 vegetable material Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- AZLASBBHHSLQDB-GUBZILKMSA-N Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C AZLASBBHHSLQDB-GUBZILKMSA-N 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108020005120 Plant DNA Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- LUMXICQAOKVQOB-YWIQKCBGSA-N Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)[C@@H](C)O LUMXICQAOKVQOB-YWIQKCBGSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- -1 glucosides saponin Chemical class 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/793,804 | 2006-02-10 | ||
| US79380406P | 2006-04-21 | 2006-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101578111A true CN101578111A (zh) | 2009-11-11 |
Family
ID=39402309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800136387A Pending CN101578111A (zh) | 2006-04-21 | 2007-04-20 | 禽流感疫苗和使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7993655B2 (https=) |
| EP (1) | EP2010210A4 (https=) |
| JP (1) | JP2009535306A (https=) |
| KR (1) | KR20080109094A (https=) |
| CN (1) | CN101578111A (https=) |
| AR (1) | AR060565A1 (https=) |
| BR (1) | BRPI0710689A2 (https=) |
| CA (1) | CA2650091A1 (https=) |
| WO (1) | WO2008060669A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665422A (zh) * | 2009-12-23 | 2012-09-12 | 疫苗基因集团 | 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法 |
| CN105074061A (zh) * | 2012-12-13 | 2015-11-18 | 美国陶氏益农公司 | 位点特异性核酸酶活性的dna检测方法 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009540801A (ja) | 2006-06-16 | 2009-11-26 | ダウ・アグロサイエンス・エル・エル・シー | トリインフルエンザ赤血球凝集素の新規なｄｎａ配列、ベクターおよびタンパク質 |
| EP2092059A4 (en) | 2006-10-24 | 2012-03-28 | Bogoch Samuel | METHOD FOR FORECASTING INFLUENZA EXCESSIONS BY CORRELATION OF AN INCREASED REPLICINE MIRROR IN WHITE SPOT AND / OR TAURA VIRUSES IN CRABES |
| CA2689181A1 (en) | 2007-05-30 | 2008-12-24 | Samuel Bogoch | Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| EP2238253B1 (en) | 2007-11-27 | 2012-09-12 | Medicago Inc. | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| SG187500A1 (en) * | 2008-01-21 | 2013-02-28 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| DK2294202T3 (en) | 2008-07-08 | 2015-08-31 | Medicago Inc | SOLUBLE RECOMBINANT INFLUENZA ANTIGENES |
| US9233148B2 (en) * | 2009-01-09 | 2016-01-12 | Samuel Bogoch | Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza |
| NZ595812A (en) * | 2009-04-23 | 2013-09-27 | Samuel Bogoch | Replikin-sequences for preventing/treating influenza and determining infectivity/lethality |
| HRP20180706T1 (hr) | 2009-06-24 | 2018-06-01 | Medicago Inc. | Kimerna gripa nalik čestici koja sadrži hemaglutinin |
| PH12012500565B1 (en) | 2009-09-22 | 2018-01-12 | Medicago Inc | Method of preparing plant-derived proteins |
| US9555093B2 (en) | 2010-04-30 | 2017-01-31 | Temasek Life Sciences Laboratory Limited | Universal vaccine against H5N1 lineages |
| TWI620816B (zh) | 2011-03-23 | 2018-04-11 | 苜蓿股份有限公司 | 植物衍生蛋白回收方法 |
| CA2842345A1 (en) | 2011-07-20 | 2013-01-24 | Samuel Bogoch | Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| CA2866170A1 (en) * | 2012-03-12 | 2013-09-19 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885248A (en) | 1984-02-15 | 1989-12-05 | Lubrizol Genetics, Inc. | Transfer vector |
| US5173410A (en) | 1984-02-15 | 1992-12-22 | Lubrizol Genetics Inc. | Transfer vector |
| CA1288073C (en) | 1985-03-07 | 1991-08-27 | Paul G. Ahlquist | Rna transformation vector |
| ATE108828T1 (de) | 1987-02-09 | 1994-08-15 | Lubrizol Genetics Inc | Hybrides rns-virus. |
| CA2071943C (en) | 1989-12-22 | 2007-04-24 | Joan Tellefsen Odell | Site-specific recombination of dna in plant cells |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| JPH07200893A (ja) | 1993-12-27 | 1995-08-04 | Toshiba Corp | 自動精算機 |
| GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
| US5916879A (en) * | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
| JP2000253876A (ja) | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
| CA2406947A1 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
| US6855536B2 (en) | 2000-07-20 | 2005-02-15 | University Of Tennessee Research Corp., Inc. | Materials and methods for the enhancement of effective root nodulation in legumes |
| DE10049587A1 (de) | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
| DE10061150A1 (de) | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| DE10109354A1 (de) | 2001-02-27 | 2002-09-05 | Icon Genetics Ag | Rekombinante virale Schaltersysteme |
| DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
| CN1533438A (zh) | 2001-06-08 | 2004-09-29 | �����Ŵ��Ƽ���˾ | 在植物生产蛋白质的方法 |
| DE10129010A1 (de) | 2001-06-13 | 2002-12-19 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| DE10143205A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Verfahren zur Proteinproduktion in Pflanzen |
| US7632981B2 (en) | 2002-04-29 | 2009-12-15 | Icon Genetics Gmbh | Process of producing environmentally safe transgenic organisms |
| NZ542933A (en) * | 2003-05-05 | 2009-08-28 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
| ATE473271T1 (de) * | 2003-05-05 | 2010-07-15 | Thompson Boyce Plant Res | Vektoren und zellen zur herstellung von aus transgenen pflanzen gewonnenen immunprotektiven zusammensetzungen |
| US7566458B2 (en) | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| ATE469231T1 (de) | 2003-11-10 | 2010-06-15 | Icon Genetics Gmbh | Von rna-virus abgeleitetes pflanzenexpressionssystem |
-
2007
- 2007-04-20 US US12/296,729 patent/US7993655B2/en not_active Expired - Fee Related
- 2007-04-20 BR BRPI0710689-0A patent/BRPI0710689A2/pt not_active IP Right Cessation
- 2007-04-20 WO PCT/US2007/067069 patent/WO2008060669A2/en not_active Ceased
- 2007-04-20 CA CA002650091A patent/CA2650091A1/en not_active Abandoned
- 2007-04-20 JP JP2009506790A patent/JP2009535306A/ja active Pending
- 2007-04-20 CN CNA2007800136387A patent/CN101578111A/zh active Pending
- 2007-04-20 EP EP07868241A patent/EP2010210A4/en not_active Withdrawn
- 2007-04-20 KR KR1020087027929A patent/KR20080109094A/ko not_active Withdrawn
- 2007-04-20 AR ARP070101721A patent/AR060565A1/es not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665422A (zh) * | 2009-12-23 | 2012-09-12 | 疫苗基因集团 | 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法 |
| CN102665422B (zh) * | 2009-12-23 | 2015-01-28 | 疫苗基因集团 | 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法 |
| CN105074061A (zh) * | 2012-12-13 | 2015-11-18 | 美国陶氏益农公司 | 位点特异性核酸酶活性的dna检测方法 |
| US9493844B2 (en) | 2012-12-13 | 2016-11-15 | Dow Agrosciences Llc | DNA detection methods for site specific nuclease activity |
| US10344322B2 (en) | 2012-12-13 | 2019-07-09 | Dow Agrosciences Llc | DNA detection methods for site specific nuclease activity |
| CN105074061B (zh) * | 2012-12-13 | 2021-03-09 | 美国陶氏益农公司 | 位点特异性核酸酶活性的dna检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7993655B2 (en) | 2011-08-09 |
| KR20080109094A (ko) | 2008-12-16 |
| WO2008060669A2 (en) | 2008-05-22 |
| CA2650091A1 (en) | 2008-05-22 |
| BRPI0710689A2 (pt) | 2012-02-22 |
| EP2010210A2 (en) | 2009-01-07 |
| EP2010210A4 (en) | 2010-07-21 |
| JP2009535306A (ja) | 2009-10-01 |
| AR060565A1 (es) | 2008-06-25 |
| WO2008060669A3 (en) | 2009-05-07 |
| US20090136532A1 (en) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101578111A (zh) | 禽流感疫苗和使用方法 | |
| US11085049B2 (en) | Influenza virus-like particle production in plants | |
| KR101956910B1 (ko) | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ) | |
| Shoji et al. | Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza | |
| US8163876B2 (en) | DNA sequences, vectors and proteins of avian influenza hemagglutinin | |
| Cornelissen et al. | A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1 | |
| CN113186173B (zh) | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 | |
| Stachyra et al. | Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens | |
| EP2358386B1 (en) | Optimized influenza vaccines | |
| Lee et al. | Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection | |
| Myc et al. | Nanoemulsion nasal adjuvant W805EC induces dendritic cell engulfment of antigen-primed epithelial cells | |
| CN104203272A (zh) | 复合抗原序列及疫苗 | |
| KR102027758B1 (ko) | 약독화된 돼지 인플루엔자 백신 및 이의 제조 방법 및 용도 | |
| CN116514991B (zh) | 一种β冠状病毒和流感嵌合抗原、其制备方法和应用 | |
| Gan et al. | Enhancing immunogenicity and protective efficacy of inactivated avian influenza H9N2vaccine with recombinant chicken IFN-α in chicken | |
| Hajam et al. | An influenza HA and M2e based vaccine delivered by a novel attenuated Salmonella mutant protects mice against homologous H1N1 infection | |
| AU2009283557B2 (en) | Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration | |
| Verminnen et al. | Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration | |
| Lei et al. | Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase | |
| Rigano et al. | Plants as biofactories for the production of subunit vaccines against bio-security-related bacteria and viruses | |
| Gebauer et al. | Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme | |
| Stepanova et al. | Amino acid substitutions N123D and N149D in hemagglutinin molecule enhance immunigenicity of live attenuated influenza H7N9 vaccine strain in experiment | |
| CN107129527B (zh) | 一种马链球菌兽疫亚种保护性抗原hp0623及其制备方法 | |
| Yang et al. | A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses | |
| CN104726416B (zh) | 提供流感病毒异源保护的病毒样颗粒及其方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091111 |